Samples

Revenue segments as reported by the company.

Test revenue

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Change in fair value of contingent consideration

Asset impairment

Restructuring

Gain on sale of RUO kit assets

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Invitae

Invitae Corp. engages in the provision of genetic information into mainstream medical practice. It includes comprehensive panels for hereditary conditions in cancer, cardiology, neurology, pediatric, and rare diseases. The company was founded by Randal W. Scott and Sean E. George on January 13, 2010 and is headquartered in San Francisco, CA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Invitae reports strong Q4 earnings, eyes growth amid challenges

Invitae's Q4 2022 performance showcased revenue growth, improved margins, and reduced cash burn, positioning the company for sustainable growth.
Strategic investments in key growth areas and a focus on customer experience and profitability underpin Invitae's vision for the future.
Addressing supply chain challenges while seizing opportunities for expansion and innovation will be critical for Invitae's continued success.

Invitae (NVTA) reports robust Q1 earnings and advances in PCM technology

Invitae's Q1 2023 earnings call highlighted strong financial performance, operational strengths, and strategic advancements in PCM technology.
The company's focus on growth, margin expansion, and debt management underscores a path towards sustainable profitability.
While facing challenges in reimbursement dynamics and competitive landscape, Invitae remains poised to capitalize on growth opportunities.

Invitae reports Q2 revenue growth, adjusts guidance amid challenges

Invitae shows progress towards profitability with improved margins and reduced cash burn.
Challenges in hereditary cancer revenue and PGX exit impact revenue guidance.
Focus on expanding customer base, improving reimbursement, and reducing cash burn.
Continuous investment in products for future growth and competitiveness.

Invitae reports robust Q3 earnings, addresses financial concerns proactively

Invitae's Q3 2023 performance was strong, with revenue growth and margin expansion. The company faces challenges in capital structure and insurance payments but is actively addressing them. Opportunities lie in revenue growth, operational improvements, and expanding genetic testing services.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Invitae is a genetic information company whose mission is to bring genetic information into routine medical practice to improve the quality of healthcare for billions of people.  Specializing in genetic diagnostics for hereditary disorders, Invitae is aggregating the world’s genetic tests into a single service with better quality, faster turnaround time, and a lower price than most single-gene diagnostic tests today.  What’s our plan? It takes three steps:  --Make genetic testing more affordable and accessible than ever before. --Build a secure and trusted genome management infrastructure. --Design a new global community for sharing genetic information to advance science and medicine.  Today, we are reinventing genetic testing by lowering the barriers for clinicians and patients to obtain diagnostic genetic information. Together we can improve healthcare for billions of people.

Invitae (NVTA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

What Makes Invitae (NVTA) a New Buy Stock

Nextdoor

The allure of Cathie Wood Stocks investing prowess has captured a large audience of investors. Yet, even amidst all of the optimism surrounding her investment strategies, prudent investors must be aware of the potential downside risks.

3 Cathie Wood Stocks to Sell Before It's Too Late

CRISPR Therapeutics

CRISPR Therapeutics may soon generate its first product revenue. Invitae, making progress in its recovery plan, could climb if it meets its goals.

Better Growth Stock: CRISPR Therapeutics vs. Invitae

SAN FRANCISCO & HOUSTON--(BUSINESS WIRE)--Aranscia, a global provider of diagnostics software, services, and testing solutions, and Invitae Corporation, a leading medical genetics company, today announced that Aranscia has acquired select assets of the YouScript personalized medication management platform from Invitae Corporation in an all-cash transaction. YouScript is a widely recognized leader in providing actionable, real-time medication risk and pharmacogenomics (PGx) insights that enable.

Aranscia Acquires YouScript from Invitae

Invitae Corporation (NYSE:NVTA ) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Hoki Luk - VP, IR and Corporate Development Ken Knight - President & CEO Ana Schrank - CFO Conference Call Participants Isabella Prugue - Leerink Partners Tom Stevens - Cowen Madison Pasterchick - Morgan Stanley Dustin Scaringe - William Blair Rachel Vatnsdal - JP Morgan Operator Good afternoon, and welcome to the Invitae Third Quarter 2023 Financial Results Conference Call. My name is Carla and I will be your operator for today's call.

Invitae Corporation (NVTA) Q3 2023 Earnings Call Transcript

The headline numbers for Invitae (NVTA) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Invitae (NVTA) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

Reported revenue of $121.2 million, a year-over-year decrease of 9%; on a pro forma basis, taking into account exited businesses and geographies, revenue increased approximately 4% Gross margin of 32.2% and non-GAAP gross margin of 52.4%; continued improvement in non-GAAP gross margin for nine consecutive quarters Reaffirming 2023 financial guidance SAN FRANCISCO , Nov. 8, 2023 /PRNewswire/ --  Invitae (NYSE: NVTA), a leading medical genetics company, today announced results for the third quarter ended September 30, 2023. "The Company executed well on key operating and financial metrics in the third quarter, and remains on track to meet or beat annual guidance," said Ken Knight, president and chief executive officer of Invitae.

Invitae Reports Third Quarter 2023 Financial Results

– Helps to detect circulating tumor DNA (ctDNA) as a biomarker in clinical research and clinical trials for solid tumor malignancies – – May provide real-time data on therapy response, support patient prognostic stratification and enable early detection of residual disease –  SAN FRANCISCO , Nov. 6, 2023 /PRNewswire/ --  Invitae (NYSE: NVTA), a leading medical genetics company, today announced enhanced chemistry of its Invitae Personalized Cancer Monitoring™ platform that helps detect circulating tumor DNA (ctDNA) as a biomarker for solid tumor malignancies. ctDNA can provide real-time insights on patient response or disease progression, support patient prognostic stratification and enable early detection of residual disease.

Invitae Launches Enhanced Chemistry of MRD Test to Better Serve Biopharmaceutical Clinical and Research Partnerships

Invitae's stock is down and it might get delisted from its stock exchange. It has a new crop of top managers, but it's running low on cash.

3 Things About Invitae Every Smart Investor Knows

SAN FRANCISCO , Nov. 1, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that it will report its third quarter 2023 financial results on Wednesday, November 8, 2023, and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m.

Invitae to Announce Third Quarter 2023 Financial Results on Wednesday, November 8, 2023

Li-Cycle Holdings Corp

While penny stocks offer high potential gains, they are among the riskiest sub-$5 investments an investor can make. The low stock price penny stocks offer often reflects weak business models, high debt, and uncertain prospects.

3 Penny Stocks That Look Like Intriguing Bets for the Long-Term

– Findings set to enhance patient care and reduce uncertainty in test results as clinicians advance precision healthcare for hereditary disease –   SAN FRANCISCO , Oct. 25, 2023 /PRNewswire/ --  Invitae  (NYSE: NVTA), a leading medical genetics company, today announced findings from the largest study to date on uncertain results from hereditary disease genetic testing. Published in JAMA Network Open , the study evaluated data from more than 1.6 million individuals undergoing multi-gene panel testing across various clinical specialty areas.

Landmark Study Reveals Magnitude of Uncertain Results in Clinical Genetic Testing for Hereditary Disease, Points to Evidence-Based Solutions to Reach Definitive Results

SAN FRANCISCO , Oct. 19, 2023 /PRNewswire/ --  Invitae  (NYSE: NVTA), a leading medical genetics company, today announced the appointment of veteran healthcare leader David Sholehvar, M.D., as chief operating officer, effective November 13, 2023.

Invitae Appoints Dr. David Sholehvar as Chief Operating Officer

– Invitae retrospective analysis reinforces the clinical actionability of following the ASBrS guidelines –  – Testing results informed clinical management and suggest that genetics-informed care may improve patient outcomes and optimize resource utilization – SAN FRANCISCO , Oct. 12 , 2023  /PRNewswire/ -- Invitae  (NYSE: NVTA), a leading medical genetics company, today announced results of its collaborative study on universal hereditary cancer genetic testing in all patients with breast cancer in a rural population in the Annals of Surgical Oncology . Conducted in collaboration with The Outer Banks Hospital (TOBH) in North Carolina from 2019 to 2022, the study analyzed the implementation of universal hereditary cancer genetic testing in all patients with breast cancer, as recommended by the American Society of Breast Surgeons (ASBrS)   guidelines  in 2019.

Rural Hospital System Demonstrates the Clinical Benefits of Implementing Universal Hereditary Cancer Testing in Patients with Breast Cancer

- Sponsor of the Heart of Genetic Counseling program and award, recognizing excellence in patient care - - These studies combined with new digital tools aim to increase access and frequency of hereditary cancer screening both before and during treatment - SAN FRANCISCO , Oct. 10, 2023 /PRNewswire/ -- Researchers from Invitae (NYSE: NVTA), a leading medical genetics company, are showcasing their work next week at the National Society of Genetic Counselors (NSGC) 42nd Annual Conference in Chicago that highlights the importance of genetics-informed patient care. In addition to its research presentations, the company will present the Heart of Genetic Counseling Award which recognizes excellence in the field of genetic counseling.

Invitae to Present Data at the National Society of Genetic Counselors 42nd Annual Conference That Supports Advancements in Medical Genomics

– First-of-its-kind authorization provides potential marketing differentiation and opportunities for largest testing category – – Testament to Invitae's product and lab quality –  – Sets the bar for expected performance and the associated data required for future regulatory approval of similar products – SAN FRANCISCO , Oct. 3, 2023 /PRNewswire/ --  Invitae  (NYSE: NVTA), a leading medical genetics company, today announced it gained FDA market authorization for its Common Hereditary Cancers Panel. This represents the first broad panel that is used to identify germline variants associated with hereditary cancer to gain market authorization from the FDA.

Invitae's Common Hereditary Cancers Panel Receives FDA Market Authorization

Late Friday, the U.S. FDA granted De Novo marketing authorization for the Invitae Common Hereditary Cancers Panel. The panel is the first of its kind to receive FDA marketing authorization.

Why Invitae Stock Popped Today

Invitae (NYSE: NVTA ) stock is on the rise Monday despite a lack of news from the medical genetics company this morning. There haven't been any new press releases or filings with the Securities and Exchange Commission (SEC) that explain why the shares of NVTA stock are up today.

Why Is Invitae (NVTA) Stock Up 28% Today?

SAN FRANCISCO , Sept. 25, 2023 /PRNewswire/ --  Invitae  (NYSE: NVTA), a leading medical genetics company, today announced the appointment of finance veteran Ana Schrank as the Company's chief financial officer (CFO), effective October 2.

Invitae Announces Appointment of Finance Veteran Ana Schrank as CFO

SAN FRANCISCO , Sept. 22, 2023 /PRNewswire/ --  Invitae  (NYSE: NVTA), a leading medical genetics company, today announced that it received a notice from the New York Stock Exchange (the "NYSE") on September 20, 2023, indicating the company is not currently in compliance with Section 802.01C of the NYSE Listed Company Manual because the average closing price of the company's common stock over a consecutive 30 trading-day period was less than $1.00 per share.

Invitae Receives Notice of Non-Compliance with NYSE Minimum Share Price Continued Listing Standard

The genetic testing company is reducing costs to improve margins.

Invitae Stock Analysis: Buy, Sell, or Hold?

Novavax

It's important to approach high-risk, high-reward stocks with caution, and only consider them if you're comfortable with some risk. Novavax and Invitae both are risky right now, but they may be heading for better days.

You Can Pick Up These High-Risk, High-Reward Stocks for Less Than $10

Invitae has struggled to turn rising revenue into profit. Last year, the company launched a strategic plan to pave the way to positive cash flow and is making some progress.

Cathie Wood Is Betting on This Struggling Stock. Should You?

Accolade

Intellia Therapeutics

Recursion Pharmaceuticals

Ark Invest has continued to trim its holdings in Nvidia although it's still a large holder. Meanwhile, the investment firm has been increasing its bets in the biotech sector.

Cathie Wood Just Sold Nvidia -- and Bought These 5 Potentially Explosive Growth Stocks Again

– Invitae adds chief commercial officer to leadership team; Innovative leader to help expand market share and drive revenue growth –  SAN FRANCISCO , Aug. 28, 2023  /PRNewswire/ -- Invitae  (NYSE: NVTA), a leading medical genetics company, today announced that it has appointed Robert (Rob) Guigley as its chief commercial officer, effective September 5, 2023. Mr. Guigley brings to the role more than 20 years of commercial experience spanning biotechnology, pharmaceuticals, diagnostics and genetic testing.

News for Invitae Stock (NVTA)